[Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D018377:Neurotransmitter Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D011379:Prognosis; D013148:Spironolactone / Q000031:analogs & derivatives / Q000627:therapeutic use; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000503:physiopathology*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D018377:Neurotransmitter Agents; D013148:Spironolactone; D000077545:Eplerenone